150,000 Shares in Certara, Inc. $CERT Bought by Nano Cap New Millennium Growth Fund L P

Nano Cap New Millennium Growth Fund L P bought a new position in Certara, Inc. (NASDAQ:CERT) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 150,000 shares of the company’s stock, valued at approximately $1,322,000. Certara comprises about 1.1% of Nano Cap New Millennium Growth Fund L P’s portfolio, making the stock its 25th biggest position.

A number of other hedge funds have also modified their holdings of the stock. Capco Asset Management LLC grew its holdings in shares of Certara by 41.6% in the 4th quarter. Capco Asset Management LLC now owns 11,469 shares of the company’s stock worth $101,000 after acquiring an additional 3,367 shares during the last quarter. FourThought Financial Partners LLC acquired a new position in shares of Certara in the 4th quarter worth $143,000. Bastion Asset Management Inc. acquired a new position in shares of Certara in the 4th quarter worth $488,000. Gamco Investors INC. ET AL acquired a new position in shares of Certara in the 4th quarter worth $90,000. Finally, Tejara Capital Ltd grew its holdings in shares of Certara by 39.7% in the 4th quarter. Tejara Capital Ltd now owns 381,552 shares of the company’s stock worth $3,361,000 after acquiring an additional 108,500 shares during the last quarter. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Barclays cut their price target on shares of Certara from $8.00 to $6.50 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. KeyCorp cut their price target on shares of Certara from $10.00 to $8.00 and set an “overweight” rating on the stock in a report on Monday, April 13th. Morgan Stanley cut their price target on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Stephens cut their price target on shares of Certara from $10.00 to $9.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Finally, Wall Street Zen lowered shares of Certara from a “buy” rating to a “hold” rating in a report on Sunday, February 15th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $8.85.

Certara Trading Up 10.7%

Shares of NASDAQ:CERT opened at $5.17 on Friday. The firm has a fifty day moving average of $5.83 and a two-hundred day moving average of $7.60. The firm has a market capitalization of $804.30 million, a P/E ratio of -51.70 and a beta of 1.53. Certara, Inc. has a 12-month low of $4.45 and a 12-month high of $13.88. The company has a quick ratio of 1.88, a current ratio of 1.88 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last issued its earnings results on Monday, May 11th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). The company had revenue of $106.92 million for the quarter, compared to analyst estimates of $106.13 million. Certara had a negative net margin of 3.60% and a positive return on equity of 3.52%. The company’s quarterly revenue was up .8% on a year-over-year basis. During the same period last year, the business earned $0.14 EPS. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. On average, equities analysts expect that Certara, Inc. will post 0.29 EPS for the current fiscal year.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.